Loading...
XWAR
NEU
Market cap804mUSD
Oct 30, Last price  
701.00PLN
1D
-0.28%
1Q
-8.96%
Jan 2017
79.74%
IPO
1,522.69%
Name

Neuca SA

Chart & performance

D1W1MN
XWAR:NEU chart
P/E
20.38
P/S
0.23
EPS
34.40
Vol. 1Y
26.48%
Shs. 5Y
0.60%
Rev. 5Y
8.07%
Div Yld LY
2.28%
Div Yld TTM
2.54%
Revenues
13.64b
+8.18%
1,700,854,0003,288,786,0003,969,629,0005,687,344,0006,131,679,0006,388,658,0005,687,431,0005,795,092,0006,568,700,0006,945,703,0007,077,194,0007,485,234,0007,753,263,0008,278,727,0009,254,014,0009,864,258,00011,232,540,00011,812,636,00012,611,751,00013,643,615,000
Net income
156m
+0.87%
11,275,00016,350,00014,104,00036,336,00037,563,00053,192,00066,016,00085,347,00093,070,000101,284,000111,727,00094,497,00098,274,000117,655,000141,791,000150,655,000137,238,000146,269,000154,244,000155,579,000
CFO
497m
+685.30%
-11,013,00084,072,00035,614,00048,994,00014,111,000166,079,000124,920,00027,696,000202,556,000180,402,000175,049,000121,764,000121,935,000202,247,000324,671,000300,198,000335,937,000288,271,00063,229,000496,535,000
Dividend
Jun 29, 202617.8 PLN/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

NEUCA S.A., headquartered in Torun, Poland, specializes in supplying pharmaceutical products to pharmacies and healthcare facilities throughout the country. The firm structures its business around distinct segments: wholesale pharmaceutical distribution, the development and marketing of proprietary drug brands, and a comprehensive healthcare services division. This healthcare arm specifically encompasses outpatient care, clinical trials, and telemedicine. Beyond these core areas, NEUCA S.A. provides an extensive array of additional services, including marketing and advertising support, agency functions, financial solutions, logistics through road cargo transport, accounting and bookkeeping, software development, information technology support, and specialized services for hospitals. The company also offers various insurance products—covering health, property, and other personal lines—and operates its own network of medical supply stores. Established in 1990 as Torfarm SA, the company rebranded to NEUCA S.A. in April 2010.

Related entities

Subsidiaries (3)
SWIAT ZDROWIA OPERATOR MEDYCZNY SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA
TOWARZYSTWO UBEZPIECZEN ZDROWIE SPOLKA AKCYJNA
KAPADI ITALY S.R.L.

Key people

Kazimierz Herba
Chairman of the Supervisory Board · since 2009
President of the Management Board · since 2026
Deputy Chairman of the Supervisory Board · since 2023
Wieslawa Herba
Deputy Chairwoman of the Supervisory Board · since 2009
Julita Czyzewska
Vice President of the Management Board, Patient Area · since 2022
Roman Dudzik
Vice President of the Management Board, Area of Technology and Data · since 2022
Krzysztof Miszewski
Vice Chairman of the Management Board - Operations · since 2023
Daniel Wojtkiewicz
Vice President of the Management Board, Sales Division · since 2022
Piotr Sucharski
Vice-Chairman of the Supervisory Board · since 2026
Member of the Supervisory Board · since 2018
Iwona Sierzputowska
Member of the Supervisory Board · since 2020
Bozena Sliwa
Member of the Supervisory Board · since 2011
Member of the Supervisory Board · since 2009
IPO date
Sep 30, 2004
Employees
3,981
Domiciled in
PL
Incorporated in
PL
Headquarters & legal address
TORUŃ FORTECZNA 35-37
TORUŃ, 04 87-100
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT